Volume 3, Issue 2, April 2018, Page: 14-19
Correlations Between Administration of Food Supplements with Marked Antioxidant Properties and Clinical Parameters in Patients with Prostate Carcinoma
Torricelli Piera, Department of Urology, Hospital "A. Cardarelli", Campobasso, Italy
Antonelli Francesco, Department of Biology, University of Tor Vergata, Rome, Italy
Ferorelli Pasquale, Department of Biology, University of Tor Vergata, Rome, Italy
Shevchenko Anna, Department of Science, People’s Friendship University of Russia, Moscow, Russia
Lenzi Stefano, Department of Medicine, Université Européenne Jean Monnet, Bruxelles, Belgium
Beninati Simone, Department of Biology, University of Tor Vergata, Rome, Italy
Received: Mar. 26, 2018;       Accepted: Apr. 12, 2018;       Published: May 10, 2018
DOI: 10.11648/j.ijcocr.20180302.11      View  762      Downloads  46
Abstract
Several studies indicate that high oxidative stress is associated with various degenerative diseases, including tumors. The high levels of free radicals present in many patients derive from the chronic lack of antioxidants, caused by an increasingly poor and artificial diet. The study presented in this research, conducted on 50 male volunteers, carriers of Prostatic Carcinoma (PCa) at different stages of development and under current therapy, showed that the daily intake of antioxidants contained in two food supplements, Citozym (CIZ) and Propulzym (PRZ), induces a significant increase of the ratio free/total PSA and also a reduction of various clinical parameters, correlated with PCa. This result suggests a potential slowdown in the progression of the disease. This study was planned on the basis of a recent preliminary trial, that highlighted the positive activity of CIZ in a model of benign prostatic hypertrophy. Studies are in progress to identify the components present in these food supplements affecting biochemical signals, elements that underlie the ability of PCa to progress. This does not mean that the intake of antioxidants is a cure for PCa, but that a high undiagnosed oxidative stress, much less correct by the standard oncological approaches, contributes to the evolution of the tumor disease. In other words, current oncology focuses correctly on reducing the tumor mass, but does not intervene on the biological medium that produced it. This is why there is still a dramatic incidence of relapses.
Keywords
Food Supplements, Antioxidants, Prostate Carcinoma, Oxidative Stress
To cite this article
Torricelli Piera, Antonelli Francesco, Ferorelli Pasquale, Shevchenko Anna, Lenzi Stefano, Beninati Simone, Correlations Between Administration of Food Supplements with Marked Antioxidant Properties and Clinical Parameters in Patients with Prostate Carcinoma, International Journal of Clinical Oncology and Cancer Research. Vol. 3, No. 2, 2018, pp. 14-19. doi: 10.11648/j.ijcocr.20180302.11
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Rahul K. Lall, Deeba N. Syed, Vaqar M. Adhami, Mohammad Imran Khan, and Hasan Mukhtar. Dietary Polyphenols in Prevention and Treatment of Prostate Cancer. Int J Mol Sci. 2015; 16 (2): 3350–3376.
[2]
Byeongsang Oh, Gemma Figtree, Daniel Costa, Thomas Eade, George Hruby, Stephanie Lim, Aymen Elfiky, Neil Martine, David Rosenthal, Stephen Clarke, Michael Back. Oxidative stress in prostate cancer patients: A systematic review of case control studies. Prostate Int. 2016; 4: 71-87.
[3]
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level. N Engl J Med. 2004; 350(22): 2239-2246.
[4]
Huakang Tu, Jian Gu, Qing H. Meng, Jeri Kim, Sara Strom, John W. Davis, Yonggang He, Elizabeth A. Wagar, Timothy C. Thompson, Christopher J. Logothetis, and Xifeng Wu. Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett. 2017 Mar; 13(3): 1949–1957.
[5]
Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008; 100(3):170-183.
[6]
Torricelli P., Ferorelli P., De Martino A., Antonelli F., Beninati S. Preventive effects of a mixture of micronutrients with antioxidative properties on experimentally induced prostate hyperplasia American Journal of Life Sciences. 2013; 1(1): 22-26.
[7]
Sadowska-Bartosz I, Bartosz G. Effect of antioxidants supplementation on aging and longevity. Biomed Res Int. 2014;2014:404680.
[8]
Jaouad Bouayed, Torsten Bohn. Exogenous antioxidants: Double-edged swords in cellular redox state: Health beneficial effects at physiologic doses versus deleterious effects at high doses. Oxid Med Cell Longev. 2010 Jul-Aug; 3(4): 228–237.
[9]
Terrence M. Vance, Joseph Su, Elizabeth T. H. Fontham, Sung I. Koo, and Ock K. Chun.Dietary Antioxidants and Prostate Cancer: A Review. Nutr Cancer. 2013; 65(6): 217-220.
[10]
Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C. Testosterone and prostate cancer: Revisiting old paradigms. Eur Urol. 2009; 56: 48–56.
[11]
Klap J, Schmid M, Loughlin KR. The relationship between total testosterone levels and prostate cancer: A review of the continuing controversy. J Urol. 2015; 193: 403–413.
[12]
Morgentaler A. Testosterone and prostate cancer: An historical perspective on a modern myth. Eur Urol. 2006; 50: 935–939.
[13]
García-Cruz E, Piqueras M, Huguet J, Peri L, Izquierdo L, Musquera M, Franco A, Alvarez-Vijande R, Ribal MJ, Alcaraz A. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU Int. 2012; 110: E541–E546.
[14]
Botto H, Neuzillet Y, Lebret T, Camparo P, Molinie V, Raynaud JP. High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosterone. J Urol. 2011; 186: 1400–1405.
Browse journals by subject